

Diabetes 2030 Forecasts, 2015

DALLAS-FW Metropolitan Area Diabetes Data & Forecasts

Includes: Dallas-Fort Worth-Arlington, TX Metropolitan Statistical Area

Metro Total Population Forecasts	2015	2020	2025	2030
Entire Population	7,221,300	7,945,200	8,750,400	9,451,300
Prediabetes	2,036,800	2,314,900	2,625,800	2,839,900
Diagnosed diabetes	609,700	794,600	983,900	1,147,500
Undiagnosed diabetes	216,300	267,700	314,500	347,500
Total with diabetes (diagnosed and undiagnosed)	826,000	1,062,300	1,298,400	1,495,000
Complications:				
Visual impairment	100,000	126,500	152,000	172,100
Renal failure	1,450	1,830	2,180	2,460
Leg amputations	1,260	1,510	1,720	1,850
Annual deaths attributable to diabetes	6,570	8,170	9,610	10,610
Total annual cost (2015 dollars)	\$7.5 B	\$9.6 B	\$11.7 B	\$13.5 B
Annual medical costs	\$5.7 B	\$7.2 B	\$8.8 B	\$10.1 B
Annual nonmedical costs	\$1.8 B	\$2.4 B	\$2.9 B	\$3.4 B

Metro Senior Population Forecasts	2015	2020	2025	2030
Population 65 and older	850,300	1,036,800	1,253,500	1,474,400
Prediabetes	433,700	528,800	639,300	751,900
Diagnosed diabetes	160,700	196,000	236,900	278,700
Undiagnosed diabetes	59,500	72,500	87,800	103,200
Total with diabetes (diagnosed and undiagnosed)	220,200	268,500	324,700	381,900
Complications:				
Visual impairment	30,100	35,700	42,100	48,200
Renal failure	500	580	680	770
Leg amputations	370	420	470	510
Annual deaths attributable to diabetes	4,530	5,470	6,240	6,680
Total annual cost (2015 dollars)	\$2.8 B	\$3.4 B	\$4.1 B	\$4.9 B
Annual medical costs	\$2.6 B	\$3.2 B	\$3.9 B	\$4.6 B
Annual nonmedical costs	\$0.2 B	\$0.2 B	\$0.2 B	\$0.3 B

These forecasts are based on the latest available national diabetes data, including U.S. Census Bureau population projections, the CDC National Diabetes Statistics Report, 2014, CDC diabetes morbidity trend reports, CDC's latest diabetes prevalence projections to 2050 and Dall, et al. "The Economic Burden of Elevated Blood Glucose Levels in 2012: Diagnosed and Undiagnosed Diabetes, Gestational Diabetes Mellitus, and Prediabetes," *Diabetes Care* 2014;37:3172-3179. These forecasts assume a steady, but conservative, reduction in the number of people with complications due to better awareness of the risks of diabetes, earlier screening and intervention, and more effective therapies.

For details and references on the Institute for Alternative Futures Diabetes 2030 Forecasting Model Methodology, visit www.altfutures.org/diabetes2030.

Research funded by Novo Nordisk Inc.